The Best on Infections, update from the 2010 ERS Conference

Marc Miravitlles¹, Giovanni Sotgiu², George Dimopoulos³, Gernot Rohde⁴, Rosella Centis⁵, Giovanni Ferrara⁶, Santiago Ewig⁷, Francesco Blasi⁸, Giovanni Battista Migliori⁵

¹ Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Hospital Clinic. CIBER de Enfermedades Respiratorias (CIBERES). Barcelona, Spain
² Hygiene and Preventive Medicine Institute, University of Sassari, Sassari, Italy
³ 2nd Department of Critical Care, Medical School, University of Athens, University Hospital ATTIKON, Athens Greece
⁴ Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
⁵ WHO Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy
⁶ Section of Respiratory Diseases, Dept. of Internal Medicine, S Maria Hospital, University of Perugia, Terni, Italy
⁷ Thoraxzentrum Ruhrgebiet, Kliniken für Pneumologie und Infektiologie, EVK Herne and Augusta-Kranken-Anstalt Bochum, Germany
⁸ Respiratory Medicine Section, Dipartimento Toraco-Polmonare e Cardiocircolatorio, University of Milan, IRCCS Fondazione Cà Granda Milan, Italy

Corresponding Author:
Giovanni Battista Migliori, MD
WHO Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy. E-mail: giovannibattista.migliori@fsm.it

Copyright 2011 by the European Respiratory Society.
Abstract
Respiratory tract infections and tuberculosis are among the leading reasons for seeking medical care. In this report the most recent advances in the field of clinical research and basic sciences of respiratory infections and tuberculosis are presented through the analysis of some of the best abstracts presented at the 20th ERS Congress in Barcelona and their subsequent publications in major journals. The role of viruses in COPD exacerbations, the importance of new biomarkers in the management and risk assessment of LRTIs, new modalities of treatment of respiratory infections as well as new tools for the diagnosis of latent and active tuberculosis in special subgroups of patients (children, immunocompromised individuals), and the new epidemiological threat of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis cases are discussed.

Key words: tuberculosis, respiratory infections, ERS Congress
Respiratory tract infections, both of viral and bacterial origin, are major causes of morbidity, and mortality in the European Union (EU) [1,2]. On the other hand, tuberculosis (TB) is still one the main public health priorities both at the European and global level [3,4]. TB sustained by multidrug-resistant (MDR) strains (resistant at least to the two most potent TB drugs, isonizid and rifampicin) and extensively drug-resistant tuberculosis strains (XDR-TB, where additional resistance to a quinolone plus a second-line injectable - amikacin, capreomycin or kanamycin - is detected) represents a real threat to TB control [5,6]. While being actively involved in international cross-cutting initiatives (TB day, World Health Day, Year of the Lung, Hermes project) [6,9], the ERS Respiratory Infection Assembly actively supports research and educational initiatives in these areas, being at the same time active partner in EU funded projects within the 6th and 7th Frameworks Programme, e.g. the network of excellence Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe (GRACE) [10] and the PAN-NET on tuberculosis [11].

This manuscript reviews some of the best contributions discussed at the 20th ERS Congress in Barcelona by members of the Respiratory Infections Assembly, and the main publications then derived from these discussions.
**Tuberculosis**

TB was high on the agenda of the conference, with 27 thematic sessions, one postgraduate course, four e-communication sessions, five oral sessions, five symposia/grand rounds and twelve thematic poster sessions. ERS peer-reviewed 495 abstracts on TB, and 350 (70%) of them were accepted for presentation in Barcelona.

Several hot TB topics were debated, ranging from epidemiology and clinical management of TB and MDR-/XDR-TB in healthy and special (HIV seropositive individuals, immunocompromised, children, migrants, etc.) populations to new insights related to bacteriological and immunological diagnosis.

**Multi-/extensively-drug resistant tuberculosis: epidemiological and clinical implications**

Important news on MDR- and XDR-TB has been presented from different settings and perspectives. TB control in large European cities has been discussed by two scientific groups working in the United Kingdom (UK). Story et al. found that TB incidence is increasing in London with 3,500 cases reported in 2009, where 1 out of 6 TB patients is homeless, drug/alcohol abuser or prisoner.

The study demonstrates that a multidisciplinary approach involving different stakeholders and coordinated by a specialized team (the so called "Find & Treat experience"), is able to increase case-finding from 44% to 75% and reduce default from 50% to 5% [12].

Kruijshaar ME et al. compared TB epidemiology in London vs. that in 6 other UK metropolitan counties between 2000 and 2008, finding that the TB incidence in London was significantly higher than in large conurbations (46 vs. 20 per 100,000 population, respectively); the identification of risk groups like young Black-Africans suggested the need for a strengthened strategy at the national level [13].

Anderson L et al. from the Health Protection Agency in London evaluated the treatment outcomes of MDR-TB patients after 2 years and their predictors. The treatment completion rate (65.5%) is far below the World Health Organization (WHO) targets, due, mainly, to poor adherence and to co-morbidities [14].

Relevant studies from Former Soviet Union (FSU) countries have been presented. Among them, Mishustin S et al. from Tomsk Oblast (Russia) demonstrated that the classical epidemiological indicators (incidence, prevalence and mortality) improved following the implementation of a sound TB control program. Similarly, treatment success rates among MDR-TB cases increased from 54.9% to 75.5% [15].
Crudu V et al. presented national trends on TB and MDR-TB epidemiology from Moldova, where an alarming increase in any primary resistance was observed associated with the increases in the prevalence of MDR-TB (from 0.5% to 22.1% between 1995 and 2009) [16].

A second contribution from the same Country described the results obtained after implementing the GenoType MTBDR plus assay to detect rifampicin and isoniazid resistance directly on smear-positive sputum specimens [17], allowing faster diagnosis and targeted treatment of MDR-TB cases in specialized centres.

TBNET and ECDC (European Centre for Disease Prevention and Control) developed a standardized tool to survey possible mismanagement of TB and MDR-TB in European TB reference centres.

Sotgiu G et al described the methodology adopted for developing the survey tool and the results of its pre-test [18], while Facchini A et al. [19] described the main findings of the clinical survey. The tool study [18] was recently published [20], together with the key results of the infection control components of the survey [21].

Overall, the survey showed that drugs in anti-TB regimens, treatment duration, dosages and TB/HIV co-infection management were not in accordance to WHO recommendations in more than 10% of the cases [18-20], while environmental and administrative infection control measures (e.g., use of respirators, isolation of infectious cases in negative pressure ventilation rooms) were frequently inadequate [21].

In Romania, one of the hot spots in Europe, only a minority of the HIV co-infected patients (38.9%) was sputum smear positive, 3.8% of the cases harboring MDR-TB strains. The treatment success rate was as low as 58.6%, while 21% of them died and 6.4% defaulted [22].

Shean K et al. identified predictors of poor treatment outcome in the South-African cohort of 115 XDR-TB patients, followed-up from 2002 to 2008, including adverse events (43% of those experiencing adverse events necessitated drug discontinuation and changes in the regimens, 16% interrupted their treatment and 3.7% died) [23].

The role of Interferon-\(\gamma\) Release Assays: a clinical and public health perspective

Two important reports, aimed at solving some of the questions presently under debate on IGRA's diagnostic accuracy, were presented (and recently published) by Sester M et al. [24,25] and by Diel R et al. [26,27], who described the findings of two systematic reviews and meta-analyses jointly carried out by TBNET and ECDC.
The first study [24,25] summarized the scientific evidence from 27 studies, showing that IGRA tests, performed on peripheral blood specimens, are of limited value to distinguish Latent TB Infection (LTBI) from active TB. In blood and extrasanguinous fluids, the pooled sensitivity was 80% and 48% for the QFT-G-IT test, and 81% and 88% for T-SPOT.TB test, respectively. In blood and extrasanguinous fluids, the pooled specificity was 79% and 82% for QFT-G-IT, and 59% and 82% for T-SPOT.TB, respectively.

Diel R et al. performed a systematic review and meta-analysis to compare the accuracy of the T-SPOT.TB and the QFT-G-IT tests with the Tuberculin Skin Test (TST) to confirm or exclude LTBI. IGRA's specificity ranged from 98-100%. Among IGRA-negative adults, only a small proportion developed TB after a follow-up of 2 years (NPV for progression: 97.8% for T-SPOT.TB and 99.8% for QFT-G-IT), while among IGRA-positive individuals this proportion ranged between 8-15%, significantly higher than 2-3% among TST-positives. These findings, based on 53 published studies, show that IGRA may present operational advantages compared with the TST in identifying latently infected individuals [26,27], although questions still remain about their accuracy for risk groups as children and immunocompromised patients.

These points are also addressed in other studies presented at the ERS Congress: Sester M et al. evaluated the diagnostic accuracy of the TST, T.SPOT.TB and QFT-G-IT tests in a cohort of immunocompromised patients including 652 HIV+ and 262 chronic renal failure cases [28]. In HIV-positive individuals with <200 CD4+ T cells/µl, the proportion of positive tests was higher for both IGRA tests than for the TST (6.6%; P=0.008). Higher statistically significant proportions of positive results, not associated with different M. tuberculosis exposure, were detected in individuals affected by chronic renal failure if compared with those in HIV-infected patients. In both immunocompromised populations the agreement between IGRA was moderate (k> 0.5) while was fair (k> 0.2) between IGRA and TST [28].

Ruhwald M et al. analyzed the effect of corticosteroids treatment on QFT-G-IT in 265 patients with inflammatory bowel and rheumatological diseases and the diagnostic agreement between QFT-G-IT and TST. A significant lower in vitro IFNγ response was found in immunocompromised individuals owing to corticosteroid therapy as well as a higher probability of indeterminate IGRA results (adjusted odds ratio= 8.7, P <0.05) when compared with patients not treated with corticosteroids. Concordance between QFT-G-IT and TST positivity was poor [29].
Similar findings were observed in a cohort from Timisoara, Romania, where the proportion of positive TST results was significantly higher among immunocompetent vs. immunocompromised individuals (27.7% vs. 10.3%, P= 0.001), while no significant difference in positive results was obtained using the QFT-G-IT test between the two cohorts (25.8% vs. 23.4%, respectively). Indeterminate QFT-G-IT tests were more frequently observed among immunocompromised individuals (20.7% vs. 5.5%, P= 0.021) [30].

A UK survey on the use of IGRAs to diagnose LTBI in HIV seropositive patients demonstrated that the majority of the surveyed centres (63%) used these novel tests, although their application in this cohort of immunocompromised individuals is not totally supported in the present national NICE guidelines [31]. One of the main finding of this study was that the majority of the clinical settings surveyed do not utilize IGRAs in TST positive subjects (42%), highlighting how their use is contemplated mostly in subjects were a false negative TST is suspected [31].

On the public health side, several studies, performed in Germany [Schablon A et al., 32], Portugal [Torres Costa J et al., 33] and India [James P et al., 34], assessed the serial use of IGRAs in health care workers (HCWs).

In Germany the conversion/reversion rates of 287 HCWs was studied in 14 hospitals by serial testing of QFT-G-IT [32]. Using an uncertainty zone around the cut point (0.2-0.7UI/ml) the discrimination between unspecific variation around the diagnostic cut-off and true conversion or reversion improved [32].

In Portugal, as demonstrated on 922 HCWs, the use of an uncertainty zone between 0.2-0.7UI/ml in the range of QFT-G-IT responses might be helpful for some individuals who need further tests before LTBI treatment can be recommended [33].

An interesting study from India and Canada reported rates of conversion/reversion of QFT-G-IT in nursing trainees (n=261) and the potential risk variables associated with conversion [34]. However, no statistical association between exposure and QFT-G-IT conversion rate was observed [34].

Finally, a study from Singapore demonstrated that LTBI treatment has no influence on the T-SPOT.TB positivity during the first 2 years following beyond exposure to a TB index case. Reversion of IGRA positivity took place in 51% among treated vs. 58% among untreated contacts, with no significant difference (P= 0.39) [35].
Respiratory Infections

The number of submitted abstracts to the ERS congress in 2010 in the Respiratory Infections group (group 10.1) increased by 18% from 2009, reaching a total of 331 submissions, of which 252 (76%) were accepted. Respiratory infections (RIs) was the topic of two post-graduate courses, 3 grand round/symposia, 3 oral presentations sessions, 3 e-poster sessions and 9 thematic posters sessions. The topics covered the whole spectrum of respiratory infections, including pneumonia bronchiectasis, acute exacerbations of COPD, along with aspects related to diagnosis, assessment of severity, and management.

Risk factors and outcomes in patients with community-acquired pneumonia

Community-acquired pneumonia (CAP) is still one of the leading causes of death in the world. The identification of risk factors for poor outcome is crucial to direct empirical antibiotic therapy and supportive measures.

An international database of patients with CAP (CAPO group) reported the outcomes of 118 patients infected with HIV and pneumonia and compared them with 2790 HIV negative patients with CAP. They observed that the presence of HIV infection did not influence the clinical outcome of hospitalised patients with pneumonia (36). The delay in diagnosis may have an influence in outcome, Sanz et al. (37) analysed 1038 cases of CAP and established that an initially less severe clinical presentation was associated with delayed pneumonia diagnosis, and this less severe presentation could be a result of previous treatment with systemic corticosteroids and/or antibiotics. Patients with delayed diagnosis had a higher probability of suppurative complications.

The utility of biomarkers in CAP has been extensively studied. The German CAPNETZ network reported a series of biomarkers, among them pro-adrenomedullin was the biomarker with the best performance, and added significantly to CRB-65 score for prediction of short- and long-term mortality risk in patients admitted for pneumonia (38). Another recent report indicated that procalcitonin (PCT) was helpful in predicting adverse events, and moderately improved the predictions of mortality in higher risk classes according to PSI and CURB-65 scores (39). Of importance, the medications administered to patients with severe CAP may influence the serum levels of biomarkers and decrease their prognostic value. Snijders et al. (40) observed in a population of 176 patients admitted for CAP that the use of prednisolone had a marked influence on C-reactive protein (CRP) decline, but not on PCT.
Another report from the CAPO group indicated that patients with CAP and controlled diabetes mellitus don’t have worse outcomes compared with patients without diabetes (41); however, obesity, particularly in men, was associated in another series with higher risk of hospitalisation for CAP, explained, at least in part, by the occurrence of other chronic diseases (42).

In recent years, it has been suggested to establish health care associated pneumonia (HCAP) as an additional type of pneumonia. Polverino et al. (43) described clinical features and biomarkers of a series of 75 cases meeting HCAP criteria. These patients had frequent co-morbidities and increased levels of serum inflammatory markers, which parallels the observed increased risk of poor outcomes compared with CAP.

**New aspects of treatment of patients with lower respiratory tract infections.**

There are unmet needs in the treatment of respiratory infections. Increasing rates of resistance to the usual antibiotics and the need to prevent acute episodes in individuals colonised with bacteria in the lower airways are challenges that have to be faced in clinical practice. The prudent use of antibiotics in respiratory infections is necessary and clear guidance on when and how to use antimicrobials must be developed (44). Wang et al. (45) presented results of a randomised, double-blind, placebo-controlled trial of Antiwei, a traditional Chinese herb for the treatment of influenza A. The authors observed a reduction in the severity of symptoms and a significant increase in patient’s recovery, which merits further studies. The development of specific monoclonal antibodies will help to overcome the problem of bacterial resistance. Panobacumab is a human monoclonal antibody which is directed against *Pseudomonas aeruginosa* serotype O11 and provided promising results in the treatment of a small group of patients with ventilator associated pneumonia caused by *Pseudomonas* in a pilot study (46).

The treatment of complications or comorbidities in patients with severe pneumonia is also an important strategy to improve the outcomes. Mortensen et al. (47) conducted a cohort study in 50,119 patients older than 65 years admitted for pneumonia in the United States and observed that prior use of statins was associated with decreased occurrence of serious cardiac arrhythmia in this population.

Matkovic et al. (48) reported data from Croatia on the implementation of switch therapy in patients admitted for community-acquired pneumonia. Their results showed that despite guidelines, the switch therapy was performed significantly later than recommended, which caused significant unnecessary costs.
**Chronic bronchial infection in patients with COPD and bronchiectasis**

Treatment of chronic bronchial infection in patients with bronchiectasis is not clearly established. The use of antibiotics delivered by inhalation is an alternative due to the high concentrations of the drug achieved in the site of infection. The new liposomal formulation of inhaled ciprofloxacin has been tested in patients with bronchiectasis in small studies and demonstrated to be safe and to reduce the *P. aeruginosa* sputum density significantly (49). Another strategy would be the use of long-term oral therapy with macrolides. Dwarakanath et al. (50) reported results of the use of azithromycin at dosing schedule of 500 mg once daily for 6 days, 250 mg once daily for 6 days and 250 mg thrice weekly in patients with bronchiectasis. Their results showed a reduction in sputum volume and colour, in cough frequency and in infective exacerbations, suggesting that azithromycin may play a role in long-term management of this condition. Azithromycin has also been evaluated also in the treatment of patients with COPD. In a double-blind, placebo-controlled study using azithromycin 500 mg once daily for 3 days every month over 36 months in a group of 575 patients, the authors reported a significant reduction in days with exacerbation compared to placebo, but no difference in terms of pulmonary function, quality of life or mortality (51).

**Aetiology and outcomes of infective exacerbations of COPD**

The main cause of death in COPD is exacerbations of the disease. The aetiology of these episodes may be difficult to elucidate, with respiratory infections being responsible for the majority of cases. In a multicenter study, Cosio et al. (52) found two or more bacteria in 50% of sputum samples of patients admitted for an exacerbation of COPD by using polymerase chain reaction (PCR) technique in sputum supernatants; moreover, only 5% of patients showed no microorganism both in sputum culture and PCR. The role of viruses as triggers of exacerbations has been elegantly described by works of Mallia et al. (53,54) using a novel human model of COPD exacerbation with experimental rhinovirus infection. This infection induces high airway levels of neutrophil elastase that correlate with clinical outcomes, demonstrating the decisive role of viruses as inducers of exacerbations (53). By using the same model, the authors were able to demonstrate that viral infections may be a mechanism of increased pulmonary T cells in COPD, thus initiating an inflammatory cascade in the airways (54). The new diagnostic techniques allow a better detection rates of viruses in patients with COPD, a French study using real time PCR (RT-PCR) microarray detection methods in 53 exacerbations in 26 patients identified viruses in 43% of cases, and human metapneumovirus and human rhinovirus infection were detected in 15% and 21% cases respectively.
(55), which supports again the high frequency of viral infection as trigger of exacerbations in COPD.

*Haemophilus influenzae* is the most frequent bacterial species found in bronchial secretions, both in stable and in exacerbated patients with COPD; but the mechanisms of persistence of *Haemophilus* in the bronchial epithelium are largely unknown. Millares et al. (56) demonstrated that patients colonised with *Haemophilus* presented a decreased immune response (IgA) against this microorganisms that could be a facilitating factor for colonisation. It has been demonstrated that patients colonised, even after a course of eradicating antibiotics, will be recolonized again in a period of a few weeks (57); therefore, suggesting that these facilitating factors may persist in patients with COPD.

One of the areas of more intense research in the field of exacerbations of COPD is the search for markers of bacterial infection during an exacerbation. Results derived from a randomised clinical trial with antibiotics in exacerbated patients with COPD have shown that CRP was superior to PCT as a marker for bacterial presence and might be a valuable tool to select patients for antibiotic therapy, although is difficult to establish a cut-off point for the decision to treat with antibiotics in an individual patient (58).

Medication administered for stable COPD may have an impact on the outcome of exacerbations. The role of inhaled corticosteroids (ICS) as risk factors for the development of pneumonia has been described in long term studies in patients with COPD; however, the same studies did not describe an increase in mortality associated with pneumonia (59). In a large group of patients with COPD admitted for pneumonia, it was observed that the chronic use of ICS had no impact on severity or outcome, after adjustment for COPD severity and variables included in the pneumonia severity index (PSI) (60).

**Conclusions**

As in the last congresses in Vienna and Berlin, resistant forms of active TB and new diagnostics for TB infection continued to be hot topics also during the 20th ERS Congress in Barcelona.

New alarming reports emphasized the threat posed by MDR/XDR-TB in Eastern European and FSU countries, highlighting the changing pattern of distribution of resistant forms, especially among new cases. On the other hand, new tools have been validated to survey these forms and there
is hope that their implementation will improve early diagnosis, infection control and clinical management of MDR/XDR-TB. Cross-sectional reports have been presented about the value of IGRAs in several cohorts of patients: two systematic reviews/meta-analysis on the role of IGRAs in clinical practice led to the conclusions that blood tests are not sufficiently accurate to be used as rule-out tests for active TB and that they may present operational advantages compared with the TST for the diagnosis of LTBI, especially among groups with high rates of false positive TST results; their role in high risk groups like children and immunocompromised patients is still debated and longitudinal data from properly designed studies are still awaited.

Fortunately, lower respiratory infections including pneumonia are nowadays an area of intense research that has produced advances that hopefully are reflected in a better care of our patients. Much has been learnt as regards the role of viruses in COPD exacerbations, including the clinical and epidemiological implications of the new influenza A virus, as well as the underlying for Haemophilus influenzae as the most important bacterial pathogen in stable and exacerbated patients. Macrolides carry considerable potential in the prevention of exacerbations in patients with bronchiectasis but also in those with COPD. Important data have been contributed supporting the predictive potential of biomarkers such as procalcitonin (PCT) and adrenomedullin (ADM) and indicating that they might refine clinical prediction rules.
References


32. Schablon A, Diel R, Ringshausen F, Nienhaus A. Serial testing with the interferon-γ release assay in German healthcare workers. Eur Respir J 2010; 36 (Suppl. 54): 22s.


55. Perotin JM, Andreoletti L, Deslee G, Renois F, Dury S, Duval V, de Champs C, Lebargy F. RT-PCR microarray detection of viral respiratory pathogens demonstrated the major role of human